WO2005094849A1 - 内因性メラトニン分泌リズム改善用機能性食品、及び概日リズム改善用機能性食品 - Google Patents
内因性メラトニン分泌リズム改善用機能性食品、及び概日リズム改善用機能性食品 Download PDFInfo
- Publication number
- WO2005094849A1 WO2005094849A1 PCT/JP2005/006244 JP2005006244W WO2005094849A1 WO 2005094849 A1 WO2005094849 A1 WO 2005094849A1 JP 2005006244 W JP2005006244 W JP 2005006244W WO 2005094849 A1 WO2005094849 A1 WO 2005094849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rhythm
- whey
- melatonin secretion
- lactobacillus
- circadian rhythm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
Definitions
- the present invention relates to a functional food for improving endogenous melatonin secretion rhythm, a functional food for improving circadian rhythm, and an active ingredient of these foods, which can be expected to prevent or ameliorate sleep disorders and sleep latency problems.
- the present invention relates to a raw material, an endogenous melatonin secretion rhythm abnormality, a phase adjustment or amplitude enhancer of an endogenous melatonin secretion rhythm that can prevent or improve various disorders caused by circadian rhythm abnormality, and a circadian rhythm improving agent.
- melatonin N-acetyl-5-methoxytriptamine
- NAT N-acetyltransferase
- the hormone is involved in the introduction of photoperiodic information in photoperiodic mammals and is thought to affect reproduction, body weight, metabolic regulation, circadian rhythm control, and neuronal and endocrine functions .
- the pineal melatonin secretion level is considered to be one of sleep-related substances because it shows a dynamic state that it is low in the daytime and high in the nighttime.
- a method of administering exogenous melatonin is known as a method for overcoming such circadian rhythm disorder and melatonin secretion rhythm disorder to treat or prevent sleep disorders.
- melatonin is orally ingested from outside and the melatonin rhythm is artificially adjusted to delay sleep onset, insomnia, poor waking, time difference blur, day / night reversal phenomenon, etc.
- ⁇ Efficacy for wakefulness syndrome, time difference syndrome, work-at-back syndrome, sleep phase delay syndrome, etc. has been reported.
- Patent Document 2 proposes a thread and composition for improving the quality of sleep using muramyl peptide hydrolyzed from the cell wall of non-pathogenic lactic acid bacteria as an active ingredient.
- the improvement in sleep quality presented in this document is due to the increase in the length of the non-rapid eye movement sleep phase by inducing sleep from the immune system, which improves the endogenous melatonin secretion rhythm. It is a completely different improvement in sleep quality.
- Patent Document 1 Japanese Patent Publication No. 8-502259
- Patent Literature 2 Special Table 2003—517828
- the problem of the present invention is that it can be used on a daily basis, is excellent in safety, and effectively prevents or improves endogenous melatonin secretion rhythm disorder, circadian rhythm disorder, without ingesting exogenous melatonin. It is an object to provide a phase adjusting or amplitude enhancing agent for an endogenous melatonin secretion rhythm and a circadian rhythm improving agent.
- Another problem of the present invention is that it can be used on a daily basis, is excellent in safety, has intrinsic melatonin rhythm disorder, and various symptoms such as sleep disorder and sleep-onset latency that can be caused by circadian rhythm disorder are exogenous. It is intended to provide functional foods such as specific health foods that can be prevented or improved without ingesting sex melatonin.
- an agent for adjusting the phase of an endogenous melatonin secretion rhythm or an amplitude enhancer containing whey as an active ingredient is provided.
- the circadian rhythm improving agent which contains whey as an active ingredient is provided. Furthermore, according to the present invention, functionalities for improving endogenous melatonin secretion rhythm such as prevention or improvement of sleep disorder, prevention or improvement of sleep-sleep latency disorder, including the agent for adjusting phase or amplitude of endogenous melatonin secretion rhythm. Food is provided.
- a functional food for improving circadian rhythm such as prevention or improvement of sleep disorder, prevention or improvement of sleep onset latency disorder, comprising the circadian rhythm improving agent.
- endogenous melatonin secretion phase-adjusting or amplitude-enhancing agent containing whey as an active ingredient is orally administered to animals in need of phase adjustment or amplitude-enhancing endogenous melatonin secretion rhythm.
- Rhythm phase adjustment or amplitude enhancement method is orally administered to animals in need of phase adjustment or amplitude-enhancing endogenous melatonin secretion rhythm.
- a circadian rhythm improving method comprising orally administering an effective amount of a circadian rhythm improving agent containing whey as an active ingredient to an animal in need of circadian rhythm improvement.
- whey for producing a phase adjusting or amplitude enhancing agent for endogenous melatonin secretion rhythm or a functional food for phase adjustment or amplitude enhancing of endogenous melatonin secretion rhythm.
- the present invention also provides use of whey for producing a circadian rhythm improving agent or a functional food for improving circadian rhythm.
- the endogenous melatonin secretion rhythm phase-adjusting or amplitude-enhancing agent and circadian rhythm improving agent of the present invention contain whey with diet as an active ingredient, and can be used on a daily basis. Prevention of non-24-hour sleep / wakefulness syndrome, time difference syndrome, work-at-back syndrome, sleep apnea syndrome, middle-aged sleep disorder, etc. Or improvement can be expected.
- the functional food of the present invention includes the phase adjustment or amplitude enhancer of the endogenous melatonin secretion rhythm or the circadian rhythm improver of the present invention, various symptoms such as sleep disorders and sleep latencies may be exogenous. It is possible to prevent or improve without taking melatonin.
- FIG. 1 A dala in which the melatonin concentration in the pineal gland at 12:00 in Examples 1 and 2 was compared between groups It is fu.
- FIG. 2 is a graph comparing the concentrations of melatonin in the pineal gland at 0 o'clock in Examples 1 and 2.
- FIG. 3 is a draft comparing the NAT activity in the pineal gland at 12:00 in Examples 3 and 4 between groups.
- FIG. 4 is a graph comparing the NAT activity in the pineal gland at 0 o'clock in Examples 3 and 4.
- the agent for adjusting the phase or amplitude of the endogenous melatonin secretion rhythm of the present invention can prevent or ameliorate various disorders resulting from the disorder of the endogenous melatonin secretion rhythm, and at least the action of adjusting the phase of the rhythm or the action of increasing the amplitude. It exhibits one function and contains whey as an active ingredient.
- the circadian rhythm improving agent of the present invention exhibits an action capable of preventing or improving various disorders caused by circadian rhythm disorders, and includes whey as an active ingredient.
- the whey as the active ingredient includes a water fraction obtained by removing all or most of the casein protein from milk according to a conventional method, and includes acidic whey and Z or cheese whey.
- Acid whey includes fermented whey obtained by fermentation using lactic acid bacteria, casein whey containing a water fraction obtained by removing all or most of the casein protein in accordance with a conventional method by adding acid to milk.
- the fermenting whey typically includes fermenting whey obtained by a method of fermenting milk with lactic acid bacteria or symbiotic fermentation with lactic acid bacteria and yeast.
- the raw milk include animal milk such as cow's milk, goat's milk, and sheep milk; plant milk such as soy milk; skim milk, reduced milk, powdered milk, condensed milk and the like that are processed milks thereof. In use, it can be used as a mixture.
- the solid content concentration of milk is not particularly limited.
- non-fat milk solids when skim milk is used The shape concentration is about 9% by mass.
- the fermented whey obtained at the time of production of fermented milk can be used separately from other milk components, and when it is used as a functional food described later, it is not always necessary to separate other milk components.
- Examples of the lactic acid bacterium include lactic acid bacteria belonging to the genus Streptococcus, Ratatococcus, Lactobacillus, Bifidopacteria, etc., and the Lactobacillus genus is preferred. Specifically, for example, Lactobacillus bulgaricus, Lattobacillus helveticus, Lactobacillus helveticus, Lactobacillus helveticus
- Lactobacillus helveticus can be particularly preferably used. More specifically, Lactobacillus helveticus ATCC 15009, Lactobacillus helveticus ATCC 521, Lactobacillus helveticus CM4 strain (Ministry of Economy, Trade and Industry, National Institute of Advanced Industrial Science and Technology Deposit Center Deposit Number: FERM BP-6060, date of deposit 1997. 8. 15) (hereinafter referred to as CM4 strain), with CM4 strain being particularly preferred. This CM4 strain is registered with the above deposit number in the Budapest Treaty on the International Approval of Deposits for Microorganisms in Patent Procedures, and the patent is patented so that all restrictions not available to third parties are removed.
- the lactic acid bacterium is preferably used as a sufficiently active starter that has been pre-cultured.
- the initial bacterial count is preferably about 10 5 to: about L0 7 / ml.
- yeast When the fermented whey is used as a functional food such as food for specified health use, yeast can be used in combination during the fermentation in order to improve the flavor and the palatability.
- the strain of yeast is not particularly limited. For example, Saccharomyces cerepiche
- Saccharomyces yeasts such as (Saccharomyces cerevisiae) are preferred.
- the content of fermenting mother can be appropriately selected according to the purpose.
- the ability to culture one or more of the lactic acid bacteria in a medium, or a medium obtained by mixing one or more of the lactic acid bacteria and one or more of the yeasts can be cultured.
- a medium only one or more of the above milk components
- yeast extract vitamins such as ascorbic acid, amino acids such as cysteine, salts such as sodium chloride, sugars such as glucose, sucrose, raffinose and stachyose, and stabilizers such as gelatin
- a medium supplemented with flavor and the like can be used.
- Fermentation by conventional standing or stirred culture for example, fermentation temperature 20 to 50 ° C, preferably carried out at 30-45 ° C, the fermentation initial pH 6. 0 to 7. 0 conditions of the number of bacteria 10 7 It can be carried out by, for example, a method in which the culture is stopped when it reaches Zml or more and pH 5.0 or less. Moreover, the milk before fermentation may be subjected to high-temperature heat sterilization.
- the obtained fermentation whey can be obtained by separating from the curd by a normal separation operation.
- fermented milk containing the whey can be used as it is without separating the fermented whey as needed, and the degree of separation operation Can be appropriately determined.
- the casein whey is added to milk dissolved in distilled water, for example, lactic acid, citrate, acetic acid, tartaric acid, fumaric acid, malic acid, darconic acid. It is obtained by adding adipic acid or the like to adjust the acidity to mainly remove proteins such as casein and then separating the whey fraction (water fraction) according to a conventional method such as membrane treatment.
- the milk before adding the acid may be subjected to high-temperature heat sterilization or the like.
- the mixing ratio of the acid is usually such that the acidity is 1.0 to 4.0% in accordance with the type of the acid.
- the cheese whey is obtained by curding the curd with a rennet at the time of normal cheese production or the like, and then separating the whey by using a centrifugal separator or the like. At this time, the milk before treatment with rennet may be subjected to high-temperature heat sterilization or the like.
- the dose of sour milk whey as an active ingredient in the phase adjustment or amplitude-enhancing agent or circadian rhythm improving agent of the endogenous melatonin secretion rhythm of the present invention is not particularly limited in consideration of continuity.
- the lyophilized powder is usually at least 0.0000 lgg body weight kgZ day, preferably at least 0. OlgZ body weight kgZ day.
- the endogenous melatonin secretion rhythm phase adjusting or amplitude enhancing agent of the present invention and the circadian rhythm improving agent may be whey if necessary. It is also possible to contain other components having a circadian rhythm improving effect or a phase adjustment or amplitude enhancing effect of endogenous melatonin secretion rhythm other than the above.
- the form of the phase adjustment or amplitude enhancing agent or circadian rhythm improving agent of the endogenous melatonin secretion rhythm of the present invention is as whey as it is or as a processed product thereof, for example, as a concentrate obtained by concentrating whey under reduced pressure or the like.
- the whey can be dried by freeze-drying or spray-drying to obtain a dried powder form.
- the endogenous melatonin secretion rhythm phase adjustment or amplitude enhancing agent of the present invention or circadian rhythm improving agent can usually be administered orally, for example, endogenous melatonin secretion rhythm abnormality or circadian rhythm abnormality. Even after symptoms such as sleep disorders caused by the symptom occur, it can be taken daily or intermittently at a time to prevent such symptoms.
- the functional food for improving endogenous melatonin secretion rhythm of the present invention includes the phase adjustment or amplitude enhancer of the endogenous melatonin secretion rhythm, and the functional food for improving circadian rhythm of the present invention is the circadian food. Contains a rhythm improving agent.
- These functional foods include specific health care that has promoted the prevention and improvement of sleep disorders, the prevention of amelioration of endogenous melatonin secretion rhythm such as prevention and improvement of sleep latency, and the prevention of symptoms caused by abnormal circadian rhythms.
- Functional foods such as foods for use.
- Additives such as sugars, proteins, lipids, vitamins, minerals, flavors, or mixtures thereof may be added to the functional food. It may also contain milk components other than whey before separating whey.
- the mixing ratio of whey as the active ingredient can be appropriately selected according to the form and type of the food, and appropriately selected according to the continuity of intake of the functional food, etc. Although not particularly limited, a range of 1 to LOO% by mass is appropriate.
- each functional food examples include fermented milk products such as yogurt and lactic acid bacteria beverages, whey blended processed foods and drinks, dry powders, tablets, capsules, granules and the like.
- Each functional food of the present invention is not particularly limited in terms of dosage and administration timing. It is preferable to take it at the dosage of the active ingredient, for example, continuously or intermittently before symptoms such as endogenous melatonin secretion rhythm abnormality and circadian rhythm abnormality occur. Is preferably taken continuously or intermittently after such symptoms occur.
- skim milk powder is dissolved in distilled water to a solid content of 9% by mass, sterilized by high temperature heating at 105 ° C for 10 minutes in an autoclave, cooled to room temperature, and cultured in advance. 3% by mass of the starter was cultured and cultured at 37 ° C for 24 hours to obtain fermented milk. This fermented milk was centrifuged at 12000G for 20 minutes to remove the solids, and fermented whey was prepared. Also, commercially available skim milk powder is dissolved in distilled water to a solid content of 9% by mass, sterilized by heating at 105 ° C for 10 minutes in an autoclave, cooled to room temperature, and lactic acid has an acidity of 2. Added to 2%. Next, casein whey was prepared by centrifuging at 12000 G for 20 minutes to remove solids.
- the obtained fermented whey (Example 1) or casein whey (Example 2) was diluted to 10% by mass with distilled water and subjected to the following animal tests as drinking water. As a control, a test was also performed on a control group of distilled water not containing whey.
- the melatonin amount was measured using the trade name “Melatonin EIA Kit” (IBL Hamburg). .
- the Bradford method was used, and the trade name “Bio-Rad Protein Assay” (manufactured by Bio-Rad) was used.
- Fig. 1 shows the results of melatonin at 12 o'clock
- Fig. 2 shows the results of melatonin at 0 o'clock.
- the student-newman-keuls test was used for the significant difference test.
- the mixture was centrifuged at 500 G for 10 minutes, and 750 ml of the upper layer was dried using a centrifugal evaporator.
- mobile phase 0.1 M Taenoic Acid, 0.1 M Sodium Acetate, 35% Methanol (pH 4.1)
- the N-acetiltliptoamine produced is subjected to high performance liquid chromatography with a fluorescence detector Measured graphically.
- the measurement conditions were an excitation wavelength of 285 nm, a detection wavelength of 360 nm, a flow rate of 1 mlZ, and a force ram WakosiHI 5C18 RS (4.6 mm ⁇ 150 mm). Protein quantification was measured by the Bradford method using BSA as a standard.
- Fig. 3 shows the result of NAT activity at 12:00
- Fig. 4 shows the result of NAT activity at 0 o'clock. Note that a significant difference was used for i ⁇ student- newman- keuls test.
- Fermented milk 90% by weight including the fermented whey prepared in Example 1, product name in order to facilitate the drinking "aspartame” (manufactured by Ajinomoto Co., Ltd.) 0.05 mass 0/0, "yogurt flavor as a perfume.
- ⁇ ⁇ -3186 (manufactured by Nagaoka perfume Ltd.) 0.05 mass 0/0
- yogurt flavor DY4449
- Sugar Sugar one flavor Hase SF- 5531 (T. Hasegawa Co., Ltd.)
- further stabilizers 0.5 wt% and distilled water 9.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05727955A EP1741437A4 (en) | 2004-03-31 | 2005-03-31 | FUNCTIONAL FOOD FOR ENHANCING THE ENDOGENOUS MELATONIN SECRETION RHYTHM AND FUNCTIONAL FOOD FOR IMPROVING CIRCADIAN RHYTHM |
CN2005800175804A CN1960739B (zh) | 2004-03-31 | 2005-03-31 | 改善内源性褪黑素分泌规律用功能食品和改善昼夜节律用功能食品 |
JP2006511785A JP4891069B2 (ja) | 2004-03-31 | 2005-03-31 | 内因性メラトニン分泌リズムの位相調整又は振幅増強剤、及び概日リズム改善剤 |
US10/599,446 US20070207134A1 (en) | 2004-03-31 | 2005-03-31 | Functional food for ameliorating engogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm |
US11/952,839 US8067034B2 (en) | 2004-03-31 | 2007-12-07 | Functional food for ameliorating endogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-106153 | 2004-03-31 | ||
JP2004106153 | 2004-03-31 | ||
JP2004-166498 | 2004-06-04 | ||
JP2004166498 | 2004-06-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10599446 A-371-Of-International | 2004-03-31 | ||
US11/952,839 Continuation US8067034B2 (en) | 2004-03-31 | 2007-12-07 | Functional food for ameliorating endogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005094849A1 true WO2005094849A1 (ja) | 2005-10-13 |
Family
ID=35063515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006244 WO2005094849A1 (ja) | 2004-03-31 | 2005-03-31 | 内因性メラトニン分泌リズム改善用機能性食品、及び概日リズム改善用機能性食品 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20070207134A1 (ja) |
EP (1) | EP1741437A4 (ja) |
JP (1) | JP4891069B2 (ja) |
CN (1) | CN1960739B (ja) |
TW (1) | TW200533299A (ja) |
WO (1) | WO2005094849A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013129085A1 (ja) | 2012-03-02 | 2013-09-06 | 独立行政法人産業技術総合研究所 | 概日リズム改善剤 |
WO2015133122A1 (ja) * | 2014-03-04 | 2015-09-11 | カルピス株式会社 | 鎮静用の自律神経調整剤及び日周リズム改善剤 |
JP2016104802A (ja) * | 2016-02-15 | 2016-06-09 | 三基商事株式会社 | 睡眠改善剤 |
KR20160130779A (ko) | 2014-03-25 | 2016-11-14 | 가부시키가이샤 야쿠르트 혼샤 | 수면의 질 개선제 |
JPWO2018052020A1 (ja) * | 2016-09-13 | 2019-06-24 | めぐみ 田中 | 睡眠障害改善剤及び睡眠障害の改善方法 |
JP2020198791A (ja) * | 2019-06-06 | 2020-12-17 | 雪印メグミルク株式会社 | 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料 |
WO2022196488A1 (ja) * | 2021-03-15 | 2022-09-22 | 森永乳業株式会社 | Qolを改善するための組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150147298A1 (en) * | 2006-07-24 | 2015-05-28 | CortControl, Inc. | Sleep enhancement with cortisol reduction medical food |
CN102526217B (zh) * | 2011-10-13 | 2014-03-05 | 宁波海逸生物科技有限公司 | 一种增强免疫力、促进睡眠功能保健药物 |
RU2482689C1 (ru) * | 2011-12-01 | 2013-05-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Вологодская государственная молочнохозяйственная академия имени Н.В. Верещагина" | Способ производства кефира с функциональными свойствами |
US11617772B2 (en) | 2018-09-11 | 2023-04-04 | Direct Digital Llc | Nutritional supplements and therapeutic compositions comprising probiotics |
CN111903844B (zh) * | 2020-08-07 | 2022-05-13 | 中国热带农业科学院热带作物品种资源研究所 | 一种提高青贮饲料发酵品质的方法及其制得的饲料 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0923848A (ja) * | 1995-07-14 | 1997-01-28 | Calpis Food Ind Co Ltd:The | 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品 |
WO1999016862A1 (fr) * | 1997-09-26 | 1999-04-08 | Calpis Co., Ltd. | Bacterie du genre lactobacillus helveticus ayant une grande capacite de production de tripeptides, produit laitier fermente et son procede de preparation |
WO2000041572A1 (fr) * | 1999-01-11 | 2000-07-20 | Calpis Co., Ltd. | Procede de production de lait fermente renfermant un peptide inhibiteur de l'enzyme de conversion de l'angiotensine et procede de production de lactoserum |
JP2001503740A (ja) * | 1996-10-03 | 2001-03-21 | ラボラトワール ウノビオル エス.アー. | α―ラクトアルブミンに基づく組成物の使用 |
WO2003006500A1 (fr) * | 2001-07-13 | 2003-01-23 | Pierre Jouan Biotechnologies S.A. | Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3827833C1 (ja) * | 1988-08-17 | 1989-12-28 | Horst 5419 Herschbach De Meinhardt | |
US5449683A (en) * | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
DE9411450U1 (de) * | 1994-07-14 | 1994-10-06 | Delta Patent Invest AG, Vaduz | Molkepräparate |
EP0951842B1 (en) * | 1999-01-20 | 2002-12-04 | N.V. Nutricia | Infant formula |
US6444203B2 (en) * | 1999-12-20 | 2002-09-03 | Compagnie Gervais Danone | Administering bacteria to improve sleep |
-
2005
- 2005-03-31 CN CN2005800175804A patent/CN1960739B/zh not_active Expired - Fee Related
- 2005-03-31 JP JP2006511785A patent/JP4891069B2/ja active Active
- 2005-03-31 WO PCT/JP2005/006244 patent/WO2005094849A1/ja active Application Filing
- 2005-03-31 EP EP05727955A patent/EP1741437A4/en not_active Withdrawn
- 2005-03-31 US US10/599,446 patent/US20070207134A1/en not_active Abandoned
- 2005-03-31 TW TW094110323A patent/TW200533299A/zh unknown
-
2007
- 2007-12-07 US US11/952,839 patent/US8067034B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0923848A (ja) * | 1995-07-14 | 1997-01-28 | Calpis Food Ind Co Ltd:The | 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品 |
JP2001503740A (ja) * | 1996-10-03 | 2001-03-21 | ラボラトワール ウノビオル エス.アー. | α―ラクトアルブミンに基づく組成物の使用 |
WO1999016862A1 (fr) * | 1997-09-26 | 1999-04-08 | Calpis Co., Ltd. | Bacterie du genre lactobacillus helveticus ayant une grande capacite de production de tripeptides, produit laitier fermente et son procede de preparation |
WO2000041572A1 (fr) * | 1999-01-11 | 2000-07-20 | Calpis Co., Ltd. | Procede de production de lait fermente renfermant un peptide inhibiteur de l'enzyme de conversion de l'angiotensine et procede de production de lactoserum |
WO2003006500A1 (fr) * | 2001-07-13 | 2003-01-23 | Pierre Jouan Biotechnologies S.A. | Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques |
Non-Patent Citations (3)
Title |
---|
HEINE W. ET AL: "The Significance of trypthophan in human nutrition", AMINO ACID, vol. 9, 1995, pages 191 - 195, XP000676393 * |
See also references of EP1741437A4 * |
TSUBOI S. ET AL: "Hakkonyu Whey Toyo ni yoru Rat Shokataichu Melatonin Gosei eno Eikyo", NIPPON YAKUGAKUKAI NENKAI KOEN YOSHISHU, vol. 125, no. 3, 5 March 2005 (2005-03-05), pages 4330 - 0148, XP003004052 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013129085A1 (ja) | 2012-03-02 | 2013-09-06 | 独立行政法人産業技術総合研究所 | 概日リズム改善剤 |
JP2013181005A (ja) * | 2012-03-02 | 2013-09-12 | National Institute Of Advanced Industrial Science & Technology | 概日リズム改善剤 |
US10695383B2 (en) | 2012-03-02 | 2020-06-30 | National Institute Of Advanced Industrial Science And Technology | Circadian rhythm-improving agent |
WO2015133122A1 (ja) * | 2014-03-04 | 2015-09-11 | カルピス株式会社 | 鎮静用の自律神経調整剤及び日周リズム改善剤 |
JPWO2015133122A1 (ja) * | 2014-03-04 | 2017-04-06 | アサヒ飲料株式会社 | 鎮静用の自律神経調整剤及び日周リズム改善剤 |
KR20160130779A (ko) | 2014-03-25 | 2016-11-14 | 가부시키가이샤 야쿠르트 혼샤 | 수면의 질 개선제 |
US11331353B2 (en) | 2014-03-25 | 2022-05-17 | Kabushiki Kaisha Yakult Honsha | Sleep quality improver |
JP2016104802A (ja) * | 2016-02-15 | 2016-06-09 | 三基商事株式会社 | 睡眠改善剤 |
JPWO2018052020A1 (ja) * | 2016-09-13 | 2019-06-24 | めぐみ 田中 | 睡眠障害改善剤及び睡眠障害の改善方法 |
JP2020198791A (ja) * | 2019-06-06 | 2020-12-17 | 雪印メグミルク株式会社 | 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料 |
JP7428480B2 (ja) | 2019-06-06 | 2024-02-06 | 雪印メグミルク株式会社 | 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料 |
WO2022196488A1 (ja) * | 2021-03-15 | 2022-09-22 | 森永乳業株式会社 | Qolを改善するための組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN1960739B (zh) | 2010-06-16 |
US20080268065A1 (en) | 2008-10-30 |
TW200533299A (en) | 2005-10-16 |
EP1741437A4 (en) | 2009-06-24 |
US20070207134A1 (en) | 2007-09-06 |
US8067034B2 (en) | 2011-11-29 |
CN1960739A (zh) | 2007-05-09 |
EP1741437A1 (en) | 2007-01-10 |
JP4891069B2 (ja) | 2012-03-07 |
JPWO2005094849A1 (ja) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005094849A1 (ja) | 内因性メラトニン分泌リズム改善用機能性食品、及び概日リズム改善用機能性食品 | |
US6284243B1 (en) | Physiologically functional food having brain function-improving, learning ability-enhancing, and memory-enhancing functions | |
US6596301B1 (en) | Anti-stress drugs and functional foods having anti-stress effects | |
TWI826550B (zh) | 改善睡眠之組成物 | |
EP1374878A1 (en) | Method and composition for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract | |
JP4527922B2 (ja) | 非病原性乳酸菌の催眠活性 | |
JPH10309178A (ja) | ビフィズス菌を有効成分とする抗アレルギー剤および醗酵食品 | |
Van de Water et al. | Yogurt and immunity: the health benefits of fermented milk products that contain lactic acid bacteria | |
EP3479836B1 (en) | Cartilage regeneration facilitating composition | |
JP2010531840A (ja) | アトピー性皮膚炎の治療のためのラクトバチルス・ヘルベティカス菌組成物 | |
US7785633B2 (en) | Agent for preventing or suppressing hepatopathy and functional food for preventing or suppressing hepatopathy | |
JP3958456B2 (ja) | 血清脂質改善効果を有する機能性飲食品 | |
US20240156886A1 (en) | Gos pre-conditioning lactobacillus strains and gos in final formulation | |
US20230414685A1 (en) | Lactobacillus plantarum pda6 having neurological effects and compositions including the same | |
US20230180778A1 (en) | Milk fermentation process | |
WO2023079036A1 (en) | Probiotic composition comprising a lactobacillus salivarius strain, a lactobacillus camelliae strain and a bifidobacterium ruminantium strain | |
JP2021101645A (ja) | 免疫バランスの調節のための組成物 | |
JP2002212083A (ja) | コレステロール低下剤 | |
Dabur et al. | Functional dairy products and their impact on health | |
BE725166A (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511785 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727955 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580017580.4 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727955 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10599446 Country of ref document: US Ref document number: 2007207134 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10599446 Country of ref document: US |